What Is Follistatin-344?
Follistatin-344, usually shortened to FST344 or FS344, is the 344-amino-acid precursor encoded by one major human follistatin messenger-RNA form. After its signal sequence is removed, it principally gives rise to circulating follistatin-315. It is commonly discussed as a “myostatin inhibitor”, but natural follistatin binds several members of the activin branch of the transforming growth factor beta superfamily.
That broader biology is both the attraction and the problem. Blocking myostatin-related signals can increase muscle growth in animals, but activins also contribute to reproduction, blood-vessel biology, metabolism and tissue regulation. More muscle size does not automatically mean more strength, mobility or health.
The best-known human FST344 research did not inject purified follistatin-344 protein. It used an adeno-associated virus vector to deliver an FS344 gene into thigh muscles of a very small number of people with muscular dystrophy. A vial sold as “Follistatin-344” is therefore not equivalent to the studied gene therapy.
What do 344, 315 and 288 mean?
The numbers refer to amino-acid length at different biological stages. FS344 is a precursor that includes a signal peptide directing the new protein into the secretion pathway. Removal of that signal sequence yields FS315.
Alternative RNA processing can produce another precursor, FS317, which becomes FS288 after signal-peptide removal. FS288 binds strongly to heparan-sulphate structures on cell surfaces and in extracellular matrix. FS315 is more likely to circulate because its acidic tail reduces surface binding.
These forms have overlapping but different distribution and ligand effects. Treating the labels as synonyms obscures which material was measured or administered. Commercial pages sometimes use FST344 for a purified 344-residue injectable protein, yet a secreted biological system would normally process the signal peptide. A credible product description must state sequence, processing state, glycosylation and expression system.
What does follistatin do?
Follistatin wraps around and binds selected signalling proteins, preventing them from engaging their receptors. Its targets include activin A and myostatin, also called growth differentiation factor 8. Both signal through activin type II receptors and intracellular SMAD proteins.
Myostatin restrains skeletal-muscle growth. Animals and rare humans with loss of myostatin signalling can have unusually large muscles. Activin A has wider roles in reproductive hormones, inflammation, blood formation and tissue repair.
Follistatin is therefore not a myostatin-only switch. Its result depends on which isoform reaches which tissue, which ligands are present and how long binding persists.
Why is “myostatin inhibitor” an incomplete description?
Myostatin is made as a larger precursor and then processed into a signalling protein. The active dimer normally binds activin type II receptors, recruits a type I receptor and activates SMAD2 and SMAD3. Those intracellular signals help limit muscle-fibre growth. Follistatin can interrupt the pathway by surrounding the ligand before it reaches the receptor.
The difficulty is selectivity. Follistatin also binds activin A and related ligands. Activin signalling is involved in reproductive hormone control, red-blood-cell biology, inflammation, fibrosis and vascular regulation. The biological result of increasing follistatin therefore depends on tissue distribution and exposure, not simply on whether myostatin is present.
This distinction helps explain why a dramatic animal muscle phenotype does not settle the clinical question. A useful treatment would need to improve strength or function while avoiding unwanted suppression of related pathways. Measuring muscle size alone cannot establish that balance.
Gene transfer, recombinant protein and retail vials are different interventions
The name Follistatin-344 is used for three materially different ideas:
| Intervention | What is delivered | Expected exposure | Relevant human evidence |
|---|---|---|---|
| AAV-FS344 gene transfer | A viral vector carrying DNA for FS344 | Sustained expression from transduced muscle | Small Becker muscular dystrophy and inclusion-body-myositis studies |
| Recombinant follistatin protein | A manufactured, folded protein | Depends on formulation, distribution and clearance | No established controlled programme for injected FST344 in healthy users |
| Online “FST344” vial | A product label whose contents may be unverified | Unknown without validated identity and potency testing | Cannot be assumed equivalent to either intervention above |
Gene transfer makes treated cells manufacture and process the protein. A recombinant vial supplies protein directly and would have different pharmacokinetics, impurities and immune risks. A commercial research vial may not establish its sequence, folding, glycosylation or biological activity at all.
These differences are not technicalities. They prevent conversion of a gene-therapy vector amount into a protein amount and prevent clinical findings with one product class from validating another.
How was FST344 developed as a research approach?
Preclinical teams used gene transfer to make skeletal muscle produce follistatin for extended periods. AAV vectors can carry a therapeutic DNA cassette into cells. The FS344 form was selected in part because its processed FS315 product was expected to circulate and because it had lower activin affinity than the tissue-bound FS288 form.
Animal studies reported increased muscle size and strength in mice and non-human primates. Those findings supported small first-in-human studies in muscular disease.
In non-human primates, investigators injected an AAV vector encoding the human FS344 sequence into selected muscles. The study reported increases in muscle size and strength that persisted during follow-up. This was important translational evidence because primate muscle and immune responses are more clinically relevant than those of a mouse.
It was still preclinical evidence. Healthy or experimentally studied animals do not reproduce the fibrosis, fat replacement, inflammation, motor adaptation and disease progression seen in human muscular disorders. Direct intramuscular delivery also creates a concentrated local intervention rather than a uniform whole-body effect.
| Period | Development |
|---|---|
| 1980s to 1990s | Follistatin identified and its activin-binding biology defined |
| 2000s | Myostatin pathway and AAV-follistatin animal programmes expanded |
| 2010s | Small intramuscular FS344 gene-transfer studies began in muscular dystrophy and myositis |
| Current position | No approved FST344 protein medicine; gene-transfer evidence remains early and product-specific |
What did the Becker muscular dystrophy trial find?
The Phase 1/2a proof-of-principle study treated six people with Becker muscular dystrophy. AAV1.CMV.FS344 was injected directly into quadriceps muscles in both legs. Three received a lower vector-genome level and three a higher level.
Four participants improved their six-minute walk distance at the reported follow-up, by 29 to 125 metres. Two did not show meaningful improvement. Muscle samples were reported to show reduced fibrosis and changes consistent with hypertrophy, particularly at the higher vector level. No treatment-related adverse effect was identified in the small group.
This is hypothesis-generating evidence, not a definitive efficacy trial. There was no randomised placebo group. Six-minute walk performance varies with effort, learning, disease course and supportive care. With six participants, unusual or delayed adverse effects could easily be missed.
Most importantly, the intervention was local gene transfer. The reported vector genomes per kilogram per leg describe viral-vector administration, not a protein dose. They cannot be converted into milligrams of injectable Follistatin-344.
What did the biopsies and imaging add?
The study used more than a walking test. Magnetic-resonance imaging helped characterize pre-existing quadriceps fibrosis, and muscle biopsies examined fibre size, central nuclei and connective tissue. The two participants in the higher vector group who improved function also showed a shift towards larger muscle fibres and reduced fibrosis in sampled tissue.
Those findings support biological activity at the injection site, but they do not remove the study’s limitations. A biopsy samples a small region. Selecting or reaching a healthier region can affect what is seen, and tissue changes do not prove that the intervention caused a person-level improvement. The investigators also reported focal rather than diffuse quadriceps enlargement in humans.
Why is the six-minute walk result hard to interpret?
The six-minute walk test combines strength, endurance, balance, motivation and cardiopulmonary capacity. It is clinically useful, but performance can fluctuate and repeated testing can produce a learning effect. Becker muscular dystrophy also varies considerably between people.
Four improvements among six participants are interesting, especially when accompanied by tissue signals. Yet there was no concurrent control group, the cohorts were only three people each, follow-up differed by cohort, and the two non-responders had more advanced fibrosis. The results cannot separate treatment effect from participant selection, baseline disease differences, training or natural variability.
Is there other human research?
An early study also evaluated intramuscular AAV1-FS344 in six ambulatory people with sporadic inclusion-body myositis. This progressive muscle disease has different biology from Becker muscular dystrophy. The vector was delivered to quadriceps muscles in both legs, and the published report compared functional change with a small untreated natural-history group.
The authors reported improvement in distance walked over six minutes and muscle-biopsy findings interpreted as increased regeneration. The intervention was reported as well tolerated in the treated group. However, all treated participants also followed an exercise programme and received prednisone around vector administration. The comparison was not randomized or blinded, and the external control group was not exposed to the same co-interventions.
Those design choices prompted a published scientific critique arguing that the functional claims were not securely attributable to gene transfer. The investigators replied in defence of their methods and interpretation. A respectable summary needs to preserve that disagreement: the study showed feasibility and possible biological activity, but it did not provide controlled proof of efficacy.
Newer trial registrations may use other AAV serotypes, target age-related muscle decline or combine follistatin gene delivery with another gene product. A registration shows that a study is planned or under way, not that the intervention works.
No controlled clinical programme was identified in which a chemically or recombinantly manufactured FST344 vial was repeatedly injected for healthy muscle gain.
How would a follistatin protein be manufactured?
Follistatin is far larger and more structurally complex than a short synthetic peptide. It contains multiple cysteine-rich domains and disulphide bonds, and natural forms can carry sugar groups. A recombinant expression system, such as engineered mammalian cells, is more plausible than routine solid-phase synthesis for a properly folded full-length glycoprotein.
Manufacture would require a defined DNA construct and host-cell bank, controlled culture, purification, viral-safety steps and assays for identity, folding, glycosylation, aggregates, host-cell proteins and residual DNA. A ligand-binding or cell-based potency assay would be needed.
The AAV gene therapy is another product class entirely. Its active material is a viral vector carrying DNA, not follistatin protein in the vial. Vector genome identity, capsid, empty-to-full ratio, infectivity, sterility and long-term expression all matter.
A simple “99% purity” result cannot establish either product. It does not show correct isoform, biological activity, endotoxin control or absence of aggregates.
What would a credible FST344 test report need to show?
Chromatographic purity is only one attribute. For a large recombinant protein, a serious analytical package would need to address identity by intact mass and peptide mapping; correct disulphide bonding; aggregation and fragments; glycosylation where relevant; concentration; residual host-cell material; endotoxin; sterility for an injectable product; and biological potency in a validated ligand-binding or cell-signalling assay.
Even a complete certificate of analysis does not create clinical evidence. It can help show what a batch contains, but it cannot establish a safe exposure, useful indication or favourable benefit-risk balance. A seller’s document also requires traceable sample custody and an identifiable, competent laboratory before it deserves evidentiary weight.
What are the safety concerns?
The human database is too small to quantify safety. Biological concerns include unintended activin-family inhibition, reproductive-hormone effects, altered blood-vessel signalling and effects in tissues beyond muscle.
Gene therapy adds immune responses to the viral capsid, inflammation, inability to easily withdraw long-lived expression and uncertainty about distribution. Local injection may still lead to circulating protein.
Growth of muscle without proportional adaptation of tendon, connective tissue, heart or motor control could create a mismatch. Larger muscle is not automatically functional muscle.
Because follistatin pathways intersect with cancer biology in complex and tissue-dependent ways, simplistic claims that follistatin either causes or prevents cancer are not justified. Long-term surveillance would be necessary in a therapeutic programme.
Is Follistatin-344 approved or permitted in sport?
No Follistatin-344 protein product is an approved medicine. AAV-FS344 remains an experimental gene-transfer approach.
The World Anti-Doping Agency prohibits agents that modify myostatin function and prohibits gene and cell doping. Athletes should regard follistatin products and follistatin gene transfer as prohibited. Product contamination and mislabelling do not excuse an anti-doping finding.
What claims are not established?
Evidence does not establish commercially sold FST344 vials for bodybuilding, strength, sports recovery, fat loss, healthy ageing or injury repair. It does not establish a safe injection amount, cycle or combination.
The gene-therapy results cannot be transferred to purified protein because exposure, location, duration, processing and immune risks differ. Animal hypertrophy does not establish patient-important human benefit.
How strong is the evidence overall?
| Question | Best available evidence | What can reasonably be concluded |
|---|---|---|
| Can FS344 expression affect human muscle tissue? | Small AAV gene-transfer studies with biopsies | Biological activity is plausible and tissue changes were observed |
| Does it improve function in muscular disease? | Tiny uncontrolled studies with mixed results | A signal exists, but efficacy is unproven |
| Does injected recombinant FST344 work? | No adequate controlled human programme identified | No reliable conclusion |
| Does it benefit healthy adults or athletes? | No controlled human evidence | Claims are unsupported |
| Is long-term use safe? | Very limited participants and follow-up | Risk frequency and long-term consequences are unknown |
This is where the evidence genuinely runs out. More words cannot supply missing randomized trials, pharmaceutical product characterization or long-term surveillance.
Frequently asked questions
Is Follistatin-344 a peptide?
It is a large protein precursor, not a typical short research peptide.
Is FST344 the same as FS315?
No. FS344 includes a signal peptide and is processed principally to FS315.
Is it the same as FS288?
No. FS288 comes from a different precursor and binds more strongly to cell-surface structures.
Does follistatin block myostatin?
Yes, but it also binds other activin-family ligands.
Has FST344 been tested in people?
An FS344 gene cassette has been delivered by AAV in very small muscular-disease studies. That is not the same as injecting purified FST344 protein.
Did the Becker trial prove benefit?
No. It was an uncontrolled six-person early trial with mixed individual responses.
Does it build muscle in healthy people?
No controlled human evidence establishes that use.
Is Follistatin-344 approved?
No FST344 protein medicine is approved.
Is it gene therapy?
FST344 is a protein form, but the principal human research used gene therapy to make muscle express it.
Can gene-therapy amounts be converted into protein doses?
No. Vector genomes and milligrams of purified protein measure different interventions.
What are the main unknowns?
Long-term safety, off-target activin effects, immune effects, functional benefit and product identity remain important.
Is it prohibited in sport?
Yes, myostatin-modifying agents and gene doping fall within prohibited categories.
Are online FST344 vials equivalent to trial material?
No. They are neither the AAV vector nor proven pharmaceutical-grade follistatin.
Does this page give administration guidance?
No. Study descriptions are not recommendations.
Sources
Research reviewed through September 2026.